Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study

AimsTo evaluate the efficacy and safety of dapagliflozin plus pioglitazone versus comparators on metabolic control and hepatic steatosis in adults with type 2 diabetes mellitus (T2DM), with or without metabolic dysfunction-associated steatotic liver disease (MASLD).MethodsWe conducted a systematic r...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Shashank Joshi, Shambo Samrat Samajdar, Arvind Gupta, Mithun Bhartia, Sailesh Lodha, Supratik Bhattacharyya, Krishna Seshadri, Lakshmi Nagendra, A. G. Unnikrishnan, Dakshata Padhye, Lakshmi Nalini Kopalle, Ashok Kumar Das, Om Lakhani, Jothydev Kesavadev, Ameya Joshi, Sambit Das, Smriti Gadia, Thamburaj Anthuvan
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-07-01
Serie:	Frontiers in Clinical Diabetes and Healthcare
Soggetti:	combination therapy dapagliflozin MASLD NAFLD pioglitazone SRMA
Accesso online:	https://www.frontiersin.org/articles/10.3389/fcdhc.2026.1733995/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!